Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.
van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zettl F, Béné MC, Westers TM. van de Loosdrecht AA, et al. Among authors: oelschlaegel u. Leuk Lymphoma. 2013 Mar;54(3):472-5. doi: 10.3109/10428194.2012.718341. Epub 2012 Sep 14. Leuk Lymphoma. 2013. PMID: 22916713 Review.
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.
Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, Klut IM, Knoth H, Röllig C, Schetelig J, Mohr B, Graehlert X, Ehninger G, Bornhäuser M, Thiede C. Platzbecker U, et al. Among authors: oelschlaegel u. Leukemia. 2012 Mar;26(3):381-9. doi: 10.1038/leu.2011.234. Epub 2011 Sep 2. Leukemia. 2012. PMID: 21886171 Free PMC article. Clinical Trial.
Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.
Oelschlaegel U, Westers TM, Mohr B, Kramer M, Parmentier S, Sockel K, Thiede C, Bornhäuser M, Ehninger G, van de Loosdrecht AA, Platzbecker U. Oelschlaegel U, et al. Haematologica. 2015 Mar;100(3):e93-6. doi: 10.3324/haematol.2014.115725. Epub 2014 Nov 25. Haematologica. 2015. PMID: 25425689 Free PMC article. No abstract available.
Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden.
Oelschlaegel U, Alexander Röhnert M, Mohr B, Sockel K, Herold S, Ehninger G, Bornhäuser M, Thiede C, Platzbecker U. Oelschlaegel U, et al. Leukemia. 2016 Feb;30(2):517-20. doi: 10.1038/leu.2015.158. Epub 2015 Jun 24. Leukemia. 2016. PMID: 26104659 Free PMC article. No abstract available.
Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.
Francke S, Mies A, Meggendorfer M, Oelschlaegel U, Balaian E, Gloaguen S, Haferlach T, Ehninger G, Bornhäuser M, Platzbecker U. Francke S, et al. Among authors: oelschlaegel u. Leuk Lymphoma. 2017 May;58(5):1271-1272. doi: 10.1080/10428194.2016.1225209. Epub 2016 Sep 23. Leuk Lymphoma. 2017. PMID: 27659716 No abstract available.
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.
Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, Orfao A, Moshaver B, Brodersen LE, Loken MR, Wells DA, Subirá D, Cullen M, Te Marvelde JG, van der Velden VH, Preijers FW, Chu SC, Feuillard J, Guérin E, Psarra K, Porwit A, Saft L, Ireland R, Milne T, Béné MC, Witte BI, Della Porta MG, Kern W, van de Loosdrecht AA; IMDSFlow Working Group. Westers TM, et al. Among authors: oelschlaegel u. Haematologica. 2017 Feb;102(2):308-319. doi: 10.3324/haematol.2016.147835. Epub 2016 Oct 6. Haematologica. 2017. PMID: 27758818 Free PMC article.
Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.
van der Velden VHJ, Preijers F, Johansson U, Westers TM, Dunlop A, Porwit A, Béné MC, Valent P, Te Marvelde J, Wagner-Ballon O, Oelschlaegel U, Saft L, Kordasti S, Ireland R, Cremers E, Alhan C, Duetz C, Hobo W, Chapuis N, Fontenay M, Bettelheim P, Eidenshink-Brodersen L, Font P, Loken MR, Matarraz S, Ogata K, Orfao A, Psarra K, Subirá D, Wells DA, Della Porta MG, Burbury K, Bellos F, Weiß E, Kern W, van de Loosdrecht A. van der Velden VHJ, et al. Among authors: oelschlaegel u. Cytometry B Clin Cytom. 2023 Jan;104(1):15-26. doi: 10.1002/cyto.b.22046. Epub 2021 Dec 11. Cytometry B Clin Cytom. 2023. PMID: 34894176 Free PMC article.
47 results